What does 2026 hold?
Review the final paper in the three-part series to gain deeper
insight into global platform positioning and scalable
diagnostics infrastructure heading into 2026.
Download the full report below.
Download Request
Collaborations & Alliances in AI and omics gain prominence
in CDx and oncology.
Beyond outright acquisitions, 2025 saw a flood of
partnerships, licensing deals, and co-development
agreements in life sciences diagnostics. These deals are
often the preferred route for accessing novel technology
or entering new markets without full acquisition.
Download the full report below.
Download Request
Major players turn their M&A sights to platforms and technologies with broad application to drive growth.
Gain deeper insight into M&A resurgence and consolidation and strategic consolidation amid tariff uncertainty.
Download the full report below.
Download Request
Adrian Dawkes talks to PharmaVentures' Founder and CEO, Dr Fintan Walton, about the importance of strategy and preparation in today's deal making space. In the competitive, fast-paced environment of deal making within the life sciences industry, if you fail to prepare, then you must prepare to fail. Tune in to help assemble your strategy for success.
About the Presenter: Adrian Dawkes is a Managing Director at PharmaVentures and has been with the company since 2007. Adrian has led multiple consultancy, licensing and M&A mandates. During his professional career, Adrian has significant multi-discipline expertise spanning research and development through to sales, marketing and business development. Adrian has over 30 years' experience in the pharmaceutical, biotechnology and consultancy services sectors. Adrian holds a BSc in Biochemistry and a PhD in Immunochemistry.
Fintan Walton is the Founder and CEO of PharmaVentures. He has over 30 years’ experience helping clients achieve success in deal making. Over a period of three decades, he has built PharmaVentures into a global player in supporting transactions for blue chip corporations and emerging innovator corporations. In that time, the firm has delivered more than 1,000 transaction related assignments for companies in 38 countries.
Join Adrian Dawkes, Managing Director at PharmaVentures, for this podcast episode exploring how the pharmaceutical manufacturing sector is evolving in response to shifting global pressures. Our experts, Ross Jenkins and Dr Gurdas Singh, unpack the critical changes shaping the industry.
Adrian Dawkes is a Managing Director at PharmaVentures and has been with the company since 2007. Adrian has led multiple consultancy, licensing and M&A mandates.
During his professional career, Adrian has significant multi-discipline expertise spanning research and development through to sales, marketing and business development. Adrian has over 30 years' experience in the pharmaceutical, biotechnology and consultancy services sectors. Adrian holds a BSc in Biochemistry and a PhD in Immunochemistry.
Ross Jenkins joined PharmaVentures as a Business Analyst and has since been promoted to Director, with previous experience in diagnostic start-ups and commercialisation.
Prior to joining PharmaVentures, Ross worked at a multiplex immune-diagnostic start-up in New Zealand focused on both human and animal health. During this time he was involved across all areas of the business from communications, manufacturing, quality/regulatory affairs, and market analysis. Ross holds a BSC(Hons) in Biotechnology and, a PGDip and Masters in Bioscience Enterprise from the University of Auckland.
Dr Gurdas Singh advises on both buy-side and sell-side transactions globally. He specialises in guiding companies to optimise their positioning for partnerships and M&A opportunities across diagnostics, pharmaceutical manufacturing, and healthcare services.
Gurdas holds a Master’s of Research from The University of Oxford, securing multiple research grants and having authored over 20 publications. He also earned a Bachelor’s of Medicine and Surgery (MBBS) and a Bachelor’s of Science in Medical Sciences from King’s College London.